Navigation Links
MedAptus Customers Capitalizing on P4P Incentives via Intelligent Charge Capture
Date:7/14/2009

BOSTON, July 14 /PRNewswire/ -- MedAptus(R), market leader for charge capture technologies, today announced enthusiastic adoption of its P4P component across the company's Professional Intelligent Charge Capture user-base. MedAptus P4P is widely used for capture of quality measure data for the Physician Quality Reporting Initiative (PQRI) program, as well as localized payer efforts.

MedAptus' powerful, yet easy-to-use, technologies are practice-proven to maximize revenue, enhance compliance efforts and increase billing process transparency. In addition to both mobile and desktop-based solutions for physician professional charge capture, the company also offers the industry's only automation for the capture and management of outpatient facility charges as well as a dedicated infusion charge capture product enjoying tremendous success at top-ranked cancer centers.

MedAptus P4P is embedded within all of the various software editions that belong to the company's Professional Intelligent Charge Capture solution suite, eliminating the need for creation of separate processes for data collection. The MedAptus approach utilizes real-time alerts to prompt clinician-users to document required data elements. Only common clinical terms are presented to the user, for measures specific to his or her specialty, saving valuable time -- which customers such as Hawthorn Medical Associates truly appreciate.

"Our physicians really enjoy being able to utilize MedAptus to document their PQRI measures -- having data collection embedded into practice workflow means time-strapped providers don't have to think about whether or not an encounter is eligible for incentive. Clearly, commercial contracts are headed towards more pay-for-performance requirements, so being able to orient our doctors now, especially with such an intuitive tool, will only benefit them more in the future," said Matthew Nivison,
'/>"/>

SOURCE MedAptus
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Dartmouth-Hitchcock Medical Center Selects MedAptus for Charge Capture Deployment
2. University of Minnesota Physicians Chooses MedAptus Following Comprehensive Vendor Review
3. MedAptus Charge Capture Technology Deployed at Leading Manhattan Cardiovascular Practice
4. MedAptus Expands Board of Directors
5. MedAptus Secures $6 Million Investment
6. MedAptus Experiences Record Growth of 70 Percent
7. MedAptus Selected by Kentucky Medical Services Foundation for Professional Charge Capture Technology
8. Dana-Farber Cancer Institute Completes Deployment of MedAptus Infusion Services Module
9. Local Company Gives Out Injury Supplies at No Cost to Customers
10. Velos, Inc. Launches Velos On-Demand for Velos eResearch, Bringing Dynamically Scalable Economy to Customers
11. Customers Design Reid Supply's New Web Site
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:The Flag Company, Inc.'s Recently Released “Feel Good” Light Lenses Grows Into Its Own Website 2Health News:The Flag Company, Inc.'s Recently Released “Feel Good” Light Lenses Grows Into Its Own Website 3Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 2Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 3Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 4Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 5Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 6Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 7Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 8Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 9Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 10Health News:Winner Medical Reports Fourth Quarter and Fiscal 2009 Results 11Health News:Patriot Scientific Corporation Announces New Director 2Health News:Washington Regional Partners with U.S. Preventive Medicine to Bring a New Level of Preventive Health Care Services to Northwest Arkansas 2Health News:Washington Regional Partners with U.S. Preventive Medicine to Bring a New Level of Preventive Health Care Services to Northwest Arkansas 3Health News:Industry Coalition Reissues Advisory Against Use of Dietary Supplements as Swine Flu Remedy, Cure 2Health News:Industry Coalition Reissues Advisory Against Use of Dietary Supplements as Swine Flu Remedy, Cure 3
Other Medicine News:Health News:Agito Networks Wins the 2008 VON Magazine Innovator Award for Enterprise Mobility 2Health News:Agito Networks Wins the 2008 VON Magazine Innovator Award for Enterprise Mobility 3Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 2Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 3Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 4Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 2Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 3Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 4Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 5Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 6Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 7Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 2Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 3Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 4Health News:Hope In Action: Policymakers and Artists Promote Youth and Latino Suicide Prevention 2Health News:Hope In Action: Policymakers and Artists Promote Youth and Latino Suicide Prevention 3
Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 2Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 3For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3Eliminate the Blues with Color Therapy 54599 1Eliminate the Blues with Color Therapy 54599 2Eliminate the Blues with Color Therapy 54599 3New biofactories produce rare healing substances in the endangered Devils claw plant 54597 1New biofactories produce rare healing substances in the endangered Devils claw plant 54597 2New biofactories produce rare healing substances in the endangered Devils claw plant 54597 3Heroes of Chemistry for saving teeth clean water new high blood pressure drug 54594 1Heroes of Chemistry for saving teeth clean water new high blood pressure drug 54594 2Heroes of Chemistry for saving teeth clean water new high blood pressure drug 54594 3Heroes of Chemistry for saving teeth clean water new high blood pressure drug 54594 4